
Clessidra and Avista acquire Rottapharm
Clessidra Capital Partners and Avista Capital Partners have acquired a 50% stake in Italian drugmaker Rottapharm from the founding family in a deal that values the business at €1.7bn, according to reports.
Each private equity firm will own a 25% stake in the company.
Carlyle Group, Charterhouse Capital Partners and Advent International are reported to have submitted rival bids for the firm.
Company
Founded in 1961 and based in Monza, Rottapharm is an Italian drugmaker. The company produces Dona, a glucosamine product that improves joints, and Mucoflux, a product for heart conditions and respiratory treatment. The firm reported a €600m turnover in 2010.
People
Alessandro Grimaldi is a senior partner at Clessidra. Thompson Dean is co-CEO of Avista.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater